SAN DIEGO, CA – January 24, 2018 – BioAtla® LLC, a global biotechnology company focused on the development of Conditionally Active Biologic protein therapeutics, announced today the U.S. Food and Drug Administration has cleared BioAtla’s Investigational New Drug application for BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate, in patients with solid tumors.
CAB-AXL-ADC will be BioAtla’s first CAB investigational product to enter clinical trials in the United States.
The AXL receptor tyrosine kinase is often highly expressed in several cancer types that can lead to poor prognosis.
A principal role of AXL appears to be in sustaining a major mechanism of resistance to diverse anticancer therapies.
AXL is a factor in the repression of the innate immune response which may also limit response to treatment including immuno-oncology therapy.
While this makes the AXL receptor an attractive target for tumor therapy, the AXL receptor is also prevalent in normal tissue of several organs in the body.
To minimize on-target-off-tumor toxicity of binding to AXL receptors on normal cells, BioAtla applies its proprietary CAB technology to develop its CAB antibody-drug conjugate targeting AXL with the intent to activate binding to the AXL receptor only in the tumor microenvironment and deliver the toxic payload to the cancerous cells.